Research and Markets: A Global Survey Report on the 2009 Neuropathic Pain Market: Treatments and Prescribing Practices Revealed

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/cedd42/neuropathic_pain) has
announced the addition of the "Neuropathic Pain: Treatments and Prescribing
Practices - A Global Survey 2009" report to their offering.

With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain
(NP) remains an area of significant unmet need. NP is highly individual in its
presentation, level, underlying pathology and response to therapy. For some
patients, available therapies give satisfactory pain control. For many others,
treatments are poor or do not work at all. Therapeutic options include more than
ten drug classes, which are commonly prescribed in combinations tailored to
individual patient needs.

Interventional treatments, such as peripheral nerve block and transcutaneous
electrical nerve stimulation, are also used as physicians seek other approaches
to treating NP. This background, the individual nature of NP and the drug (or
drug combination) options used to treat patients, has created a complex
therapeutic picture.

In a therapeutic field where treatments are often unsatisfactory, physicians
seek to extent their understanding of NP in an effort to define needs and
limitations. Knowledge in these areas is also important to drug developers, who
seek a better understanding of patient needs and outcomes, as part of their own
efforts to develop more effective therapies. To meet interest in these areas,
Biopharm Reports has conducted an in-depth global survey on current treatments
and drug prescribing practices, relating to NP. This survey involved the
participation of more than 330 physicians and clinical centres in 56 countries.

Overview:

Comprehensive details of current treatments for NP, provided by more than 330
clinics in 56 countries.

In-depth information relevant to markets and opportunities in the NP field.

98% of participants are practicing physicians, working in specialised areas of
pain treatment. Of these, 78% described themselves as specialists in pain
treatment.

Leading participant countries were USA, Canada, UK, Australia, Denmark, France,
Brazil, Germany, Netherlands and Belgium.

74% of the clinical centres participating in this study were hospital pain
departments, specialised pain practices or private pain clinics. Detailed
information on the use of specific drug classes including tricyclic
antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers,
opioids, NSAIDS, cannabinoids and Capsaicin.

* Physicians have provided detailed feedback on the underlying pathologies
associated with NP, seen in their patients.
* Comprehensive information on the most frequently prescribed drugs from nine
drugs classes, including drug combinations, for the treatment of NP.
* Biopharm Reports believes this provides the most comprehensive and up-to-date
review and analysis in this area, currently available.
* A detailed analysis of interventional methods used for the treatment of NP
(e.g. peripheral nerve block, TENS).
* An assessment of average levels of pain relief achieved in the treatment of
NP, in relation to 12 underlying conditions.
* Informative views of participating physicians on current limitations,
challenges and issues relating to the treatment of NP.

Information surveyed:

* Participant details: Participant organisation, type of clinical practice or
department; type of pain physician
* NP treatment strategies: Relative proportion of drug and interventional
treatments
* Diagnoses and underlying pathologies: For example, Diabetes, post cancer
radiotherapy or chemotherapy, post general surgery, Trigeminal Neuralgia, viral
Infections, injury/trauma, post back surgery, primary back problems, complex
regional pain syndrome (CRPS), Multiple Sclerosis, central pain, Arthritis,
Others NP pathologies
* Single or combined drug treatments
* Drug classes used: For example, tricyclic antidepressants, selective serotonin
reuptake inhibitors (SSRIs), serotonin-noradrenalin reuptake inhibitors (SNRIs),
anticonvulsants, sodium channel blockers, opioids, non-steroidal
anti-inflammatory drugs, cannabinoids, Capsaicin and others
* Tricyclic Antidepressants: First, second and third most frequently used
* Non-steroidal anti-inflammatory drugs: First, second and third most frequently
used
* Cannabinoids
* Capsaicin
* Drug combinations: First, second and third most frequently used drug
combinations (i.e. combinations of two, three or more than three specific drug
classes)
* Pain relief: Pain relief profile for the major underlying pathologies (levels
of pain relief for each underlying pathology)
* Interventional treatments: use of interventional treatments such as epidural
injections, facet joint injections, facet joint denervation, large joint
injections, medical acupuncture, nerve root blocks, peripheral nerve blocks,
prolotherapy, sympathetic blocks, lumbar sympathectomy, spinal manipulation,
trigger point injections, tendon sheath/bursa injections, intrathecal injection,
spinal chord stimulation, intramuscular stimulation, TENS and others
* Clinical issues and challenges in the treatment of NP: Individual responses
from physicians to this question
* Selective serotonin reuptake inhibitors: First, second and third most
frequently used
* Any other comments on the treatment of Neuropathic Pain: Individual responses
from physicians to this question
* Serotonin-noradrenalin reuptake inhibitors: First, second and third most
frequently used
* Anticonvulsants: First, second and third most frequently used
* Sodium Channel Blockers: First, second and third most frequently used
* Opioids: First, second and third most frequently used

Key Topics Covered:

1. Introduction

2. Study Design and Conduct

3. Study Participants

4. Interventional Treatments

5. Underlying Diagnoses

6. Single or Multiple Drugs

7. Drug Classes

8. Tricyclic Antidepressants

9. Selective Serotonin Reuptake Inhibitors

10. Serotonin Noradrenalin Reuptake Inhibitors

11. Anticonvulsants

12. Sodium Channel Blockers

13. Opioids

14. Non Steroidal Anti Inflammatory Drugs

15. Drug Combinations

16. Pain Relief

17. Use of Interventional Treatments

18. Discussion

19. Participant Details

For more information visit
http://www.researchandmarkets.com/research/cedd42/neuropathic_pain

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009